Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659783 | 0.87 | PRKCI (0.34) | PRKCIHMGCRPTPN1PTPN11TYR | |
| SCHEMBL11611739 | 0.86 | ALOX15 (0.42) | PRKCIHMGCR | |
| SCHEMBL8593252 | 0.86 | TYR (0.44) | GABRA1GABRB2ELANECTSGALOX5 | |
| SCHEMBL28069733 | 0.84 | TYR (0.47) | ALOX5TYR | |
| SCHEMBL11844190 | 0.82 | TYR (0.50) | ALOX5TYR | |
| SCHEMBL11653501 | 0.82 | TYR (0.50) | ALOX5TYR | |
| SCHEMBL3549981 | 0.82 | HMGCR (0.50) | HMGCRGABRA1GABRB2ELANEALOX5 | |
| SCHEMBL6199276 | 0.80 | PTPN1 (0.41) | PRKCIGABRA1GABRB2PTPN1PTPN11 | |
| SCHEMBL6544224 | 0.79 | GABRA1 (0.52) | GABRA1GABRB2DHFR | |
| SCHEMBL4863564 | 0.77 | KDM4E (0.31) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102985489-B | Method for producing polyphenylene ether resin composition | MITSUBISHI ENG PLASTICS CORP | 2015-06-10 | — | — | CN | disclosed |
| CN-102596524-B | Production method for molded body of polyphenylene ether resin composition | MITSUBISHI ENG PLASTICS CORP | 2014-12-03 | — | — | CN | disclosed |
| CN-102869482-B | Process for production of polyphenylene ether resin molded article | MITSUBISHI ENG PLASTICS CORP | 2014-11-05 | — | — | CN | disclosed |
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014121036-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
| CN-102985489-A | Method for producing polyphenylene ether resin composition | MITSUBISHI ENG PLASTICS CORP | 2013-03-20 | — | — | CN | disclosed |
| CN-102869482-A | Process for production of polyphenylene ether resin molded article | MITSUBISHI ENG PLASTICS CORP | 2013-01-09 | — | — | CN | disclosed |
| CN-102596524-A | Production method for molded body of polyphenylene ether resin composition | MITSUBISHI ENG PLASTICS CORP | 2012-07-18 | — | — | CN | disclosed |
| CN-101128534-A | Styrene-based resin composition and method for producing the same | TORAY INDUSTRIES (JP) | 2008-02-20 | — | — | CN | disclosed |
| CN-1255386-C | Substituted fused heterocyclic compound | SANKYO CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| EP-1022272-B1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | SANKYO CO (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| CN-1280570-A | Substituted fused heterocyclic compounds | SANKYO CO (JP) | 2001-01-17 | — | — | CN | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SRD5A2, PPARD, SRD5A1 | PRKCI 3334/4885HMGCR 1232/4885GABRA1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.